Nail diseases: focus on onychomycosis and psoriasis

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Nail diseases caused by various species of fungi are frequently encountered in daily practice. Onychomycosis is accompanied by a number of unpleasant symptoms and is manifested by hyperkeratosis, onycholysis and other clinical signs. With age, trauma or certain somatic diseases, the natural barrier of the nail plate may be compromised, which allows the infection to develop.

In patients with psoriasis, especially those with psoriatic nail lesions and psoriatic arthritis, the incidence of onychomycosis reaches 60%. At the same time in this group of patients there are often such somatic diseases as diabetes mellitus, cardiovascular diseases and liver pathologies, which limit the choice of drugs for therapy of mycotic infections. In such cases, it is possible to prescribe topical agents with keratolytic properties and containing antimycotic agents other than azoles. With the use of these drugs, the disappearance of symptoms of mycotic infection is observed in 1-2 months. However, the drugs should be used until full regrowth of the nail plate, which usually takes 4-8 months, depending on the age of the patient.

Despite the existing difficulties in the therapy of onychomycosis in patients with psoriasis and other chronic diseases, the pharmaceutical market offers highly effective agents indicated for use in this group of patients.

全文:

受限制的访问

作者简介

K. Plieva

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Department of Health

Email: marykor@bk.ru
ORCID iD: 0000-0001-9351-1034
SPIN 代码: 4498-8034
俄罗斯联邦, Moscow

E. Denisova

Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences; Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Department of Health

Email: marykor@bk.ru
ORCID iD: 0000-0002-4887-284X
SPIN 代码: 3570-5779

Candidate of Medical Sciences

俄罗斯联邦, Moscow; Moscow

A. Panchenko

N.I. Pirogov Russian National Research Medical University

Email: marykor@bk.ru
ORCID iD: 0009-0002-9371-2412
SPIN 代码: 7015-8719

Associate Professor, Candidate of Medical Sciences

俄罗斯联邦, Moscow

E. Reznik

N.I. Pirogov Russian National Research Medical University

Email: marykor@bk.ru
ORCID iD: 0000-0001-7479-418X
SPIN 代码: 3494-9080

MD

俄罗斯联邦, Moscow

I. Korsunskaya

Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences; Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Department of Health

编辑信件的主要联系方式.
Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318
SPIN 代码: 3335-2019

Professor, MD

俄罗斯联邦, Moscow; Moscow

参考

  1. Lipner S.R., Scher R.K. Onychomycosis. J Am Acad Dermatol. 2019; 80 (4): 835–51. doi: 10.1016/j.jaad.2018.03.062
  2. Zaitz C., Campbell I., Marques S.A. et al. Compêndio de Micologia Médica. Rio de Janeiro, Brazil: Guanabara-Koogan, 2010.
  3. Gupta A.K., Versteeg S.G., Shear N.H. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017; 21 (6): 525–39. doi: 10.1177/1203475417716362
  4. Belda Junior V., Di Chiacchio N., Criado P.R. Tratado de Dermatologia. São Paulo, Brazil: Ateneu, 2014; pp. 1375–90.
  5. Papini M., Piraccini B.M., Difonzo E. et al. Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. Mycoses. 2015; 58 (11): 659–64. doi: 10.1111/myc.12396
  6. Tsentemeidou A., Vyzantiadis T.-A., Kyriakou A. et al. Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: results of a pilot study. Mycoses. 2017; 60 (12): 830–5. doi: 10.1111/myc.12681
  7. Zisova L., Valtchev V., Sotiriou E. et al. Onychomycosis in patients with psoriasis–a multicentre study. Mycoses. 2011; 55: 143–7. doi: 10.1111/j.1439-0507.2011.02053.x
  8. Ventura A., Mazzeo M., Gaziano R. et al. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther. 2017; 11: 2527–35. doi: 10.2147/dddt.s136986
  9. Schons K.R.R., Knob C.F., Murussi N. et al. Nail psoriasis: a review of the literature. An Bras Dermatol. 2014; 89 (2): 312–7. doi: 10.1590/abd1806-4841.20142633
  10. Bolognia J.L., Jorizzo J.L., Schaffer J.V. Dermatologia. New York, NY, USA: Elsevier, 2015; pp. 1251–84.
  11. Klaassen K.M.G., Dulak M.G., Van de Kerkhof P.C.M. et al. The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol. 2014; 28 (5): 533–41. doi: 10.1111/jdv.12239
  12. Gupta A.K., Lynde C.W., Jain H.C. et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol. 1997; 136 (5): 786–9. doi: 10.1046/j.1365-2133.1997.6771624.x.
  13. Tabassum S., Rahman A., Awan S. et al. Factors associated with onychomycosis in nail psoriasis: a multicenter study in Pakistan. Int J Dermatol. 2019; 58 (6): 672–8. doi: 10.1111/ijd.14364
  14. Gallo L., Cinelli E., Fabbrocini G. et al. A 15-year retrospective study on the prevalence of onychomycosis in psoriatic vs non-psoriatic patients: a new European shift from dermatophytes towards yeast. Mycoses. 2019; 62 (8): 659–64. doi: 10.1111/myc.12925
  15. Raposo I., Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015; 106 (6): 452–7. doi: 10.1016/j.ad.2015.02.005
  16. Rigopoulos D., Papanagiotou V., Daniel R. III, et al. Onychomycosis in patients with nail psoriasis: a point to point discussion. Mycoses. 2017; 60 (1) :6–10. doi: 10.1111/myc.12542
  17. André J., Sass U., Richert B. et al. Nail pathology. Clin Dermatol. 2013; 31 (5): 526–39. doi: 10.1016/j.clindermatol.2013.06.005
  18. Leibovici V., Hershko K., Ingber A., et al. Increased prevalence of onychomycosis among psoriatic patients in Israel. Acta Derm Venereol. 2008; 88 (1): 31–3. doi: 10.2340/00015555-0323
  19. Alves N.C.P.O.P., Moreira T.A., Malvino L.D.S. et al. Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy. Dermatol Res Pract. 2020; 2020: 7209518. doi: 10.1155/2020/7209518
  20. Draelos Z.D. The Efficacy and Tolerability of Turmeric and Salicylic Acid in Psoriasis Treatment. Psoriasis (Auckl). 2022; 12: 63–71. doi: 10.2147/PTT.S360448
  21. Torti J.F., Correa R. Potassium Iodide. 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.
  22. Tiwari N., Pandit R., Gaikwad S. et al. Biosynthesis of zinc oxide nanoparticles by petals extract of Rosa indica L., its formulation as nail paint and evaluation of antifungal activity against fungi causing onychomycosis. IET Nanobiotechnol. 2017; 11 (2): 205–11. doi: 10.1049/iet-nbt.2016.0003
  23. Сакания Л.Р., Тогоева Л.Ш., Оленич И.В. и др. Особенности терапии онихомикозов на фоне псориаза. Клиническая дерматология и венерология. 2017; 16 (4): 62–5 [Sakaniia L.R., Togoeva L.Sh., Olenich I.V. et al. Characteristic features of treatment of onychomycosis with underlying psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2017; 16 (4): 62–5 (in Russ.)]. doi: 10.17116/klinderma201716462-65

补充文件

附件文件
动作
1. JATS XML
下载
2. Change of nail plates in patient Zh.: a – before treatment; б – after 3 months of treatment

下载 (118KB)
索引源数据

版权所有 © Russkiy Vrach Publishing House, 2025